Related Experiment Videos
Biological bypass in cardiovascular surgery.
1Department of Cardiovascular Surgery, Christian-Albrecht University of Kiel, School of Medicine, Kiel, Germany. lutter@kielheart.uni-kiel.de
The Thoracic and Cardiovascular Surgeon
|August 5, 2004
Summary
Growth factors like fibroblast growth factors (FGF) can stimulate blood vessel growth (angiogenesis and arteriogenesis) to treat ischemic diseases. This biological bypass approach offers new hope for patients ineligible for traditional revascularization.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Molecular Biology
Background:
- Ischemic heart and peripheral artery diseases pose significant clinical challenges.
- Current treatments for severe ischemia have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the physiological importance of cytokines in inducing angiogenesis and arteriogenesis.
- To discuss the potential of growth factors as a therapeutic 'biological bypass' for ischemic conditions.
Main Methods:
- Review of experimental and clinical studies on growth factors, particularly fibroblast growth factors (FGF).
- Analysis of data on the induction of capillary and collateral artery growth in ischemic tissues.
Main Results:
- Fibroblast growth factors (FGF) significantly enhance endogenous blood flow rerouting via collateral vessels.
- Therapeutic enhancement of preexisting arteriole proliferation can create a biological bypass.
- Adequate large arterioles and capillary networks are crucial for compensating perfusion deficits.
Conclusions:
- Protein and gene therapy using growth factors present a promising avenue for treating critically ill patients with ischemic diseases.
- Patients with unrevascularizable ischemic areas are potential candidates for biological bypass therapy.
- Angiogenesis and arteriogenesis can be therapeutically modulated to improve outcomes in ischemic conditions.